Adenosine, N-[(3S)-tetrahydro-3-furanyl]-

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: Adenosine, N-[(3S)-tetrahydro-3-furanyl]-
• 英文别名: (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[[(3S)-oxolan-3-yl]amino]purin-9-yl]oxolane-3,4-diol
• 化学式: C₁₄H₁₉N₅O₅
• 分子量: 337.33
• InChiKey: OESBDSFYJMDRJY-TWBCTODHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  135
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• N6 heterocyclic substituted adenosine derivatives
  申请人：CV THERAPEUTICS, INC.

  公开号：EP0992510B1

  公开（公告）日：2003-03-12
• ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS
  申请人：Gahl William A.

  公开号：US20130109645A1

  公开（公告）日：2013-05-02

  Disclosed are a method of treating or preventing a disorder in a mammal comprising administering to the mammal an adenosine receptor agonist or an adenosine receptor antagonist, either alone or in combination, in an amount effective to treat or prevent medial vascular or joint capsule calcification. Disclosed are methods of detecting or diagnosing a vascular or joint capsule calcification disorder, as well as a nucleic acid comprising a mutation in one or more exons of human NT5E selected from the group consisting of Exon 3, Exon 5, and Exon 9.
• [EN] ADENOSINE A1 RECEPTOR AGONIST FOR USE IN TREATMENT OF STATUS EPILEPTICUS<br/>[FR] AGONISTE DU RÉCEPTEUR A1 DE L'ADÉNOSINE POUR UTILISATION DANS LE TRAITEMENT DE L'ÉTAT DE MAL ÉPILEPTIQUE
  申请人：CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN

  公开号：WO2017137528A1

  公开（公告）日：2017-08-17

  The present invention is directed to an adenosine A1 receptor agonist for use in treatment of status epilepticus, in particular to theuse of N-cyclohexyl-2'-O-methyladenosine (SDZ WAG 994)in the treatment of status epilepticuswithout prior epileptogenesis and refractory to treatment with an anticonvulsive drug.